Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
Neurocrine Biosciences (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, has announced its participation in four major investor conferences this September. The company's leadership team, including CEO Kyle Gano, CFO Matt Abernethy, and other executives, will present at the Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, Baird Global Healthcare Conference, and TD Cowen Novel Mechanisms Summit.
The presentations will be accessible via live webcasts on Neurocrine's website, with replays available for approximately one month. The company specializes in developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders, with FDA-approved treatments for conditions including tardive dyskinesia, Huntington's disease chorea, and endometriosis.
Neurocrine Biosciences (Nasdaq: NBIX), azienda biofarmaceutica focalizzata sulle neuroscienze, ha annunciato la partecipazione a quattro importanti conferenze per investitori questo settembre. Il team dirigente, guidato dall'amministratore delegato Kyle Gano e dal direttore finanziario Matt Abernethy, insieme ad altri dirigenti, presenterà al Cantor Global Healthcare Conference, al Morgan Stanley Global Healthcare Conference, al Baird Global Healthcare Conference e al TD Cowen Novel Mechanisms Summit.
Le presentazioni saranno trasmesse in diretta via webcast sul sito di Neurocrine, con replay disponibili per circa un mese. L'azienda è specializzata nello sviluppo di terapie per disturbi neurologici, neuroendocrini e neuropsichiatrici e dispone di terapie approvate dalla FDA per condizioni quali la discinesia tardiva, la corea di Huntington e l'endometriosi.
Neurocrine Biosciences (Nasdaq: NBIX), una empresa biofarmacéutica centrada en neurociencia, ha anunciado su participación en cuatro importantes conferencias para inversores este septiembre. El equipo directivo, encabezado por el CEO Kyle Gano y el CFO Matt Abernethy, junto con otros ejecutivos, presentará en el Cantor Global Healthcare Conference, el Morgan Stanley Global Healthcare Conference, el Baird Global Healthcare Conference y el TD Cowen Novel Mechanisms Summit.
Las presentaciones se podrán seguir mediante webcasts en vivo en la página web de Neurocrine, con reproducciones disponibles durante aproximadamente un mes. La compañía se especializa en desarrollar tratamientos para trastornos neurológicos, neuroendocrinos y neuropsiquiátricos, y tiene terapias aprobadas por la FDA para afecciones como la discinesia tardía, la corea de Huntington y la endometriosis.
Neurocrine Biosciences (나스닥: NBIX)는 신경과학 중심의 주요 바이오제약사로, 이번 9월 네 곳의 주요 투자자 컨퍼런스에 참가한다고 발표했습니다. CEO 케일리 게이노(Kyle Gano), CFO 매트 애버네시(Matt Abernethy) 등 경영진이 Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, Baird Global Healthcare Conference 및 TD Cowen Novel Mechanisms Summit에서 발표할 예정입니다.
발표는 Neurocrine 웹사이트를 통한 라이브 웹캐스트로 시청할 수 있으며, 재생 영상은 약 한 달간 제공됩니다. 이 회사는 신경계, 신경내분비계 및 신경정신과적 질환 치료제 개발을 전문으로 하며, 지연성 운동장애(말초증 포함), 헌팅턴병 무도증, 자궁내막증 등 FDA 승인 치료제를 보유하고 있습니다.
Neurocrine Biosciences (Nasdaq: NBIX), une société biopharmaceutique axée sur les neurosciences, a annoncé sa participation à quatre grandes conférences investisseurs en septembre. L'équipe dirigeante, incluant le PDG Kyle Gano, le directeur financier Matt Abernethy et d'autres cadres, présentera au Cantor Global Healthcare Conference, au Morgan Stanley Global Healthcare Conference, au Baird Global Healthcare Conference et au TD Cowen Novel Mechanisms Summit.
Les présentations seront accessibles via des webcasts en direct sur le site de Neurocrine, avec des replays disponibles pendant environ un mois. La société est spécialisée dans le développement de traitements pour les troubles neurologiques, neuroendocriniens et neuropsychiatriques, et dispose de traitements approuvés par la FDA pour des affections telles que la dyskinésie tardive, la chorée de Huntington et l'endométriose.
Neurocrine Biosciences (Nasdaq: NBIX), ein auf Neurowissenschaften spezialisiertes biopharmazeutisches Unternehmen, hat seine Teilnahme an vier großen Investorenkonferenzen im September angekündigt. Das Führungsteam, darunter CEO Kyle Gano und CFO Matt Abernethy sowie weitere Führungskräfte, wird beim Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, Baird Global Healthcare Conference und TD Cowen Novel Mechanisms Summit präsentieren.
Die Präsentationen werden als Live-Webcasts auf der Neurocrine-Website verfügbar sein; Wiedergaben stehen für etwa einen Monat zur Verfügung. Das Unternehmen spezialisiert sich auf die Entwicklung von Therapien für neurologische, neuroendokrine und neuropsychiatrische Erkrankungen und verfügt über von der FDA zugelassene Behandlungen für Erkrankungen wie tardive Dyskinesie, Chorea bei Huntington und Endometriose.
- None.
- None.
- Chief Financial Officer Matt Abernethy, Chief Commercial Officer Eric Benevich, and Vice-President of Investor Relations Todd Tushla will present at the Cantor Global Healthcare Conference 2025 at 1:00 p.m. ET on Wednesday, September 3, 2025.
- Chief Executive Officer Kyle Gano and Chief Medical Officer Sanjay Keswani will present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 10:45 a.m. ET on Tuesday, September 9, 2025.
- Chief Executive Officer Kyle Gano, Chief Medical Officer Sanjay Keswani, and Vice-President of Investor Relations Todd Tushla will present at the Baird 2025 Global Healthcare Conference at 10:15 a.m. ET on Wednesday, September 10, 2025.
- Chief Executive Officer Kyle Gano and Vice-President of Investor Relations Todd Tushla will present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry and Epilepsy Virtual Summit at 12:40 p.m. ET on Wednesday, September 17, 2025.
The live webcasts can be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcasts will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X and Facebook.
(*in collaboration with AbbVie)
NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-upcoming-investor-conferences-in-september-302539287.html
SOURCE Neurocrine Biosciences, Inc.
FAQ
When and where will Neurocrine Biosciences (NBIX) present at the Morgan Stanley Healthcare Conference 2025?
How can investors access Neurocrine Biosciences' (NBIX) conference presentations in September 2025?
What therapeutic areas does Neurocrine Biosciences (NBIX) focus on?
Which executives from Neurocrine Biosciences (NBIX) will present at the Cantor Global Healthcare Conference 2025?
